Fitness Trends Global Oncology Drugs Market | Page 2

1. Roche is a world leader in oncology, which is engaged in developing new approaches for
advanced cancer treatment. Roche operates in two segments, which includes
pharmaceuticals and diagnostics with annual sales of US$ 39.1 Bn and US$ 11.5 Bn
respectively. Roche is at the forefront of cancer immunotherapy with ten investigational
drug candidates currently in the clinical development phase. In 2016, the company
entered into 10 new clinical collaboration agreements to explore drug combinations for
maximizing therapeutic benefits and develop the lead immunotherapy drug. The company
has set up imCORE, a network of 21 academic institutions working with Roche to
advance research into cancer immunotherapies, thus contributing to enhance the global
oncology drugs market in the near future.
2. Johnson and Johnson operates in three business segments namely consumer,
pharmaceutical and medical devices. The business of Johnson & Johnson is conducted by
more than 230 operating companies located in 60 countries worldwide. In 2016, the
company has invested around US$ 9.1 Bn in research and development activities.
Janssen, the pharmaceutical division of J&J registered the oncology drug sales of around
US$ 5.9 Bn among the total pharmaceutical therapeutic area sales. Janssen is focused on
strategic collaborations for the development of cancer therapeutics, which in turn favors
the oncology drugs market. For instance, in November, 2017, Janssen collaborated with
Zymeworks, Inc. to develop six bispecific antibodies based on Azymetric and Effector
Function Enhancement and Control Technology (EFECT) platforms for research,
development, and commercialization with a potential to generate US$ 1.5 Bn. High sales
of IMBRUVICA (ibrutinib) and DARZALEX (daratumumab) were due to increasing patient
uptake, additional country launches, and additional indications, which contributed to the
growth of oncology drugs.
3. Pfizer, Inc. develops oncology therapies that provide maximum efficacy while minimizing
adverse effects on the patient. The current portfolio of oncology drugs covers a range of
cancers. The company studies these therapies alone and in combination with other
treatments to improve the lives of cancer patients. Pfizer’s overall strategy is anchored on
innovation for developing new medicines and vaccines through collaborations and
business relationships which is expected to bolster the oncology drugs market. For
instance, Pfizer partnered with Merck KGaA for building a strong portfolio in immuno-
oncology, Biolnvent International AB to develop antibodies to advance the novel
technology platform of cancer vaccine as well as business relationship with IBM Watson